A study reported by prominent scientists that IPI 504, a potent HSP90 inhibitor, has shown therapeutic response in patients with NSCLC, especially those with anaplastic lymphoma kinase gene rearrangements [68]. This evidence concerns the gene ALK and non-small cell lung carcinoma.